Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations.


Journal

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
ISSN: 0317-1671
Titre abrégé: Can J Neurol Sci
Pays: England
ID NLM: 0415227

Informations de publication

Date de publication:
07 2020
Historique:
entrez: 14 7 2020
pubmed: 14 7 2020
medline: 14 7 2021
Statut: ppublish

Résumé

The Canadian Multiple Sclerosis Working Group has updated its treatment optimization recommendations (TORs) on the optimal use of disease-modifying therapies for patients with all forms of multiple sclerosis (MS). Recommendations provide guidance on initiating effective treatment early in the course of disease, monitoring response to therapy, and modifying or switching therapies to optimize disease control. The current TORs also address the treatment of pediatric MS, progressive MS and the identification and treatment of aggressive forms of the disease. Newer therapies offer improved efficacy, but also have potential safety concerns that must be adequately balanced, notably when treatment sequencing is considered. There are added discussions regarding the management of pregnancy, the future potential of biomarkers and consideration as to when it may be prudent to stop therapy. These TORs are meant to be used and interpreted by all neurologists with a special interest in the management of MS.

Identifiants

pubmed: 32654681
pii: S0317167120000669
doi: 10.1017/cjn.2020.66
doi:

Substances chimiques

Immunosuppressive Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

437-455

Auteurs

Mark S Freedman (MS)

The University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

Virginia Devonshire (V)

University of British Columbia, Vancouver, British Columbia, Canada.

Pierre Duquette (P)

Centre hospitalier de l'Université de Montréal, Montreal, Québec, Canada.

Paul S Giacomini (PS)

Montreal Neurological Institute and Hospital, Montreal, Québec, Canada.

Fabrizio Giuliani (F)

University of Alberta, Edmonton, Alberta, Canada.

Michael C Levin (MC)

University of Saskatchewan, Saskatoon, Saskatchewan, Canada.

Xavier Montalban (X)

St. Michael's Hospital, Toronto, Ontario, Canada.

Sarah A Morrow (SA)

London Health Sciences Centre, London, Ontario, Canada.

Jiwon Oh (J)

St. Michael's Hospital, Toronto, Ontario, Canada.

Dalia Rotstein (D)

St. Michael's Hospital, Toronto, Ontario, Canada.

E Ann Yeh (EA)

The Hospital for Sick Children, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH